3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
24
Genitourinary
6
Breast
6
Gastrointestinal
5
Other hematologic neoplasm
3
Lymphoid
3
Thoracic
2
Sarcoma
1
Other
1
CNS
1
Conditions
Sarcoma
6
Triple Negative Breast Neoplasms
2
Pathologic Complete Response
2
Osteosarcoma
2
Hemangiosarcoma
2
Breast Neoplasms
2
Bone Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Rectal Neoplasms
1
Patient Compliance
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Melanoma
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Leukemia, Myeloid, Acute
1
Leiomyosarcoma
1
Histiocytoma, Malignant Fibrous
1
Esophageal Neoplasms
1
Endometrial Clear Cell Adenocarcinoma
1
Disease Progression
1
Colonic Neoplasms
1
Chondrosarcoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
17
pembrolizumab
12
Doxorubicin
10
fludarabine
7
Irinotecan
7
Blood Specimen Collection
7
Temozolomide
6
Gemcitabine
6
Etoposide
6
Radiotherapy
5
Ifosfamide
5
Carboplatin
5
Albumin-Bound Paclitaxel
5
tecogalan
4
cemiplimab
4
Vincristine
4
Trabectedin
4
Paclitaxel
4
Nivolumab
4
Filgrastim
4
Drug Therapy
4
Dexamethasone
4
Bevacizumab
4
pazopanib
3
olaparib
3
nilotinib
3
dostarlimab
3
aflibercept
3
Therapeutics
3
Taxes
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
Standard of Care
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled